CAROSI, Giampiero
 Distribuzione geografica
Continente #
NA - Nord America 21.894
AS - Asia 11.641
EU - Europa 8.858
SA - Sud America 2.250
AF - Africa 221
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 23
Totale 44.915
Nazione #
US - Stati Uniti d'America 21.544
CN - Cina 4.266
SG - Singapore 3.825
UA - Ucraina 2.843
BR - Brasile 1.916
HK - Hong Kong 1.398
DE - Germania 1.360
IT - Italia 1.350
FI - Finlandia 752
VN - Vietnam 645
FR - Francia 572
GB - Regno Unito 513
TR - Turchia 461
IE - Irlanda 446
RU - Federazione Russa 441
IN - India 365
BD - Bangladesh 197
CA - Canada 171
SE - Svezia 165
PL - Polonia 137
AR - Argentina 114
MX - Messico 108
IQ - Iraq 73
ZA - Sudafrica 63
PK - Pakistan 60
EC - Ecuador 59
BE - Belgio 51
ID - Indonesia 50
CO - Colombia 44
NL - Olanda 44
JP - Giappone 42
AT - Austria 36
VE - Venezuela 36
ES - Italia 35
MA - Marocco 35
UZ - Uzbekistan 35
SA - Arabia Saudita 34
AE - Emirati Arabi Uniti 26
AU - Australia 26
KE - Kenya 24
MU - Mauritius 23
IR - Iran 22
LT - Lituania 21
EU - Europa 20
PY - Paraguay 20
CL - Cile 19
MY - Malesia 18
CZ - Repubblica Ceca 17
UY - Uruguay 17
EG - Egitto 16
JM - Giamaica 14
JO - Giordania 14
NG - Nigeria 14
PE - Perù 14
IL - Israele 13
AZ - Azerbaigian 11
DZ - Algeria 10
CR - Costa Rica 9
HN - Honduras 9
OM - Oman 9
PH - Filippine 9
PT - Portogallo 9
TN - Tunisia 9
BO - Bolivia 8
BF - Burkina Faso 7
QA - Qatar 7
CH - Svizzera 6
DO - Repubblica Dominicana 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LB - Libano 6
NI - Nicaragua 6
PA - Panama 6
RO - Romania 6
TT - Trinidad e Tobago 6
AL - Albania 5
BG - Bulgaria 5
BH - Bahrain 5
GR - Grecia 5
HU - Ungheria 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
AM - Armenia 4
BB - Barbados 4
ET - Etiopia 4
GT - Guatemala 4
KR - Corea 4
LK - Sri Lanka 4
LV - Lettonia 4
NP - Nepal 4
PS - Palestinian Territory 4
SI - Slovenia 4
BY - Bielorussia 3
GE - Georgia 3
GY - Guiana 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
MN - Mongolia 3
Totale 44.876
Città #
Woodbridge 2.189
Fairfield 2.160
Jacksonville 2.082
Singapore 2.015
Ashburn 1.646
Hong Kong 1.396
Houston 1.206
Wilmington 1.144
Ann Arbor 1.023
Cambridge 951
Chandler 945
Nanjing 839
Seattle 811
Princeton 807
The Dalles 769
San Jose 715
Beijing 605
Dublin 443
New York 417
Istanbul 358
Lauterbourg 358
Helsinki 309
Los Angeles 307
Nanchang 290
Ho Chi Minh City 237
Buffalo 223
Des Moines 205
Shenyang 200
Moscow 189
São Paulo 176
Hebei 175
Changsha 174
Milan 161
San Diego 147
Tianjin 141
Jiaxing 131
Warsaw 131
Jinan 130
Dearborn 119
Hanoi 116
Munich 104
Kunming 97
Shanghai 95
Hangzhou 83
Dallas 80
Verona 79
San Francisco 76
Lancaster 64
Redondo Beach 64
Chicago 62
Santa Clara 60
Toronto 60
Rio de Janeiro 59
Brescia 58
Kocaeli 56
Zhengzhou 55
Orem 54
Brussels 51
Rome 50
Guangzhou 47
Lanzhou 47
London 46
Mexico City 44
Nuremberg 44
Frankfurt am Main 42
Ningbo 41
Tokyo 39
Boardman 38
Montreal 38
Turku 38
Brooklyn 37
Belo Horizonte 36
Council Bluffs 35
Tashkent 34
Taizhou 32
Johannesburg 30
Curitiba 29
Washington 29
Leawood 28
Campinas 27
Da Nang 27
Denver 27
Brasília 26
Manchester 26
Atlanta 25
Norwalk 25
Porto Alegre 25
Stockholm 25
Baghdad 24
Chennai 24
Haikou 24
Haiphong 24
Phoenix 24
Pune 24
Biên Hòa 23
Guarulhos 23
Charlotte 21
Nairobi 21
Ribeirão Preto 21
Boston 20
Totale 29.007
Nome #
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA 251
Cos’è la Medicina Tropicale 250
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 227
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 210
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 202
Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons 201
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 197
Hepatitis C infection influence on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3 192
HIV-associated asymmetric lipodystrophy syndrome 183
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 183
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 180
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 178
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 177
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 177
Trigger-oriented HIV testing at Internal Medicine hospital Departments in Northern Italy: an observational study (Fo.C.S. Study) 176
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 175
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 173
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 171
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 171
Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. 170
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 170
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 169
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 168
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 168
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 167
Accidental and transfusion malaria in Italy 165
Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients 165
A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009 165
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 164
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 162
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 162
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 162
HYALURONIC ACID AND LIVER STIFFNESS REDUCTION IN HIV-HEPATITIS-C (HCV) COINFECTED PATIENTS TREATED WITH A CCR5 INHIBITOR MARAVIROC (MVC) IN A RANDOMIZED CONTROLLED TRIAL (MAICOL STUDY-48-WEEK ANALYSIS) 160
Key Questions in antiretroviral therapy: Italian Consensus Workshop (2005) 159
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 158
Access site-related infection in dialysis: the AStRID project: a multicenter prospective Italian study. 157
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. 156
Long-Term Response in Patients Receiving Haart Including Nelfinavir: Experience from Two Italian Centers 155
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 155
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 155
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 155
Access to antiretroviral therapy and disease progression in HIV+ migrants in Brescia, Italy 154
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 154
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 154
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study 154
Caratteri generali dei protozoi patogeni per l’uomo e delle infezioni protozoarie umane 153
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 153
Filariasis in travelers presenting to the Geosentinel Surveillance Network 153
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 152
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 151
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 150
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis 150
Adherence to surgical site infection guidelines in Italian cardiac surgery units. 150
STI epidemics in the Indian Ocean Region: can the phase be assessed? 148
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 148
Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. 148
Interleukin-2 therapy in patients with HIV infection 148
Il panorama internazionale dell’epidemia : il rischio di AIDS nel Viaggiatore Internazionale 147
Fatal disseminated toxoplasmosis during primary HIV infection. 146
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 146
Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network 145
Characteristics of schistosomiasis in travelers reported to the GeoSentinel Surveillance Network 1997-2008 145
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. 145
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 144
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies 144
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 144
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 144
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. 143
High prevalence of radiological vertebral fractures in HIV-infected males 143
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 142
VAGINAL COLONIZATION WITH CANDIDA SPP IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED WOMEN: A COHORT STUDY 140
Multicenter GeoSentinel analysis of rickettsial diseases in international travelers, 1996-2008 139
Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. 139
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 139
Malaria and HIV in adults: When the parasite runs into the virus 138
Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of Foscarnet versus Ganciclovir. 137
Towards HCV extinction with modern HCV treatment? “Yes we can!” 137
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 136
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial 136
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 135
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 135
Baggage Malaria in Italy: Cryptic Malaria explained? 134
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. 134
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. 134
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 134
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 134
Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma 134
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 134
Polymorphic immune restoration syndrome after effective HAART 133
HIV-related liver disease: ARV drugs, coinfection, and other risk factors. 133
Animal-associated exposure to rabies virus among travelers, 1997–2012 133
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 133
Risk factors for myocardial infarction in HIV positive patients 131
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 131
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 131
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy 131
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 130
Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006 130
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 130
Mortality for liver disease in patients with HIV infection: a cohort study 130
Totale 15.564
Categoria #
all - tutte 214.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 214.967


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021115 0 0 0 0 0 0 0 0 0 0 0 115
2021/20222.828 125 538 11 185 31 170 94 190 168 433 282 601
2022/20232.769 457 24 31 232 268 820 3 272 424 25 86 127
2023/20242.154 138 68 128 149 82 370 57 53 663 23 17 406
2024/20255.883 26 18 28 594 866 515 679 186 620 362 1.212 777
2025/202610.863 1.085 1.626 850 1.711 850 694 1.722 430 654 803 309 129
Totale 45.325